Ensysce Biosciences, Inc.
ENSC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001716947
In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in Ensysce Biosciences, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- +2 vs. Q3 2021
- Shares held
- 3.38M
- +222.0K (+7.0%) vs. Q3 2021
- Total value
- $15.9M
- +$6.31M (+66.0%) vs. Q3 2021
- New holders
- 8
- 4 more added
- Sold out
- 6
- 3 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ENSC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 18 | $261.1K |
| Q1 2026 | 15 | $261.5K |
| Q4 2025 | 17 | $461.1K |
| Q3 2025 | 17 | $833.7K |
| Q2 2025 | 11 | $398.8K |
| Q1 2025 | 9 | $903.4K |
| Q4 2024 | 8 | $1.15M |
| Q3 2024 | 13 | $580.5K |
| Q2 2024 | 11 | $253.0K |
| Q1 2024 | 10 | $236.5K |
| Q4 2023 | 9 | $56.4K |
| Q3 2023 | 12 | $231.1K |
| Q2 2023 | 9 | $714.0K |
| Q1 2023 | 10 | $103.2K |
| Q4 2022 | 14 | $138.2K |
| Q3 2022 | 20 | $810.7K |
| Q2 2022 | 21 | $3.41M |
| Q1 2022 | 21 | $6.23M |
| Q4 2021 | 18 | $15.9M |
| Q3 2021 | 16 | $9.56M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Ensysce Biosciences, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| HG Vora Capital Management, LLC | 2,462,500 | $11.6M | 0.41% | 00.0% | Unchanged |
| Vanguard Group Inc | 301,299 | $1.42M | 0.00% | +301,299 | New |
| Stifel Financial Corp | 216,642 | $1.02M | 0.00% | −106,700−33.0% | Reduced |
| Goldman Sachs Group Inc | 170,648 | $802.0K | 0.00% | +170,648 | New |
| Geode Capital Management, LLC | 100,921 | $474.0K | 0.00% | +45,991+83.7% | Added |
| State Street Corp | 34,900 | $164.0K | 0.00% | +34,900 | New |
| Tower Research Capital LLC (TRC) | 32,453 | $153.0K | 0.00% | +21,860+206.4% | Added |
| Jane Street Group, LLC | 16,733 | $79.0K | 0.00% | +4,180+33.3% | Added |
| Evergreen Capital Management LLC | 14,028 | $66.0K | 0.00% | 00.0% | Unchanged |
| Cresset Asset Management, LLC | 11,223 | $53.0K | 0.00% | −2,494−18.2% | Reduced |
| UBS Group AG | 9,861 | $46.0K | 0.00% | +9,861 | New |
| Wolverine Asset Management LLC | 3,460 | $16.0K | 0.00% | +669+24.0% | Added |
| JPMorgan Chase & Co | 1,314 | $6.00K | 0.00% | +1,314 | New |
| BlackRock Inc. | 561 | $3.00K | 0.00% | +561 | New |
| FinTrust Capital Advisors, LLC | 350 | $2.00K | 0.00% | +350 | New |
| Morgan Stanley | 309 | $1.00K | 0.00% | −2,960−90.5% | Reduced |
| Wells Fargo & Company | 64 | $0 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 91 | $0 | 0.00% | +91 | New |
| Founders Fund Ill Management, LLC | 0 | $0 | 0.00% | −143,575−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −38,065−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −34,113−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −25,807−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −11,228−100.0% | Sold out |
| Covington Capital Management | 0 | $0 | 0.00% | −4,800−100.0% | Sold out |